X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glenmark Pharma Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Quarterly Results   (GLPH)

Here are the latest quarterly results of Glenmark Pharma. For more details, see the Glenmark Pharma financial fact sheet and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

Glenmark Pharma Quarterly Results

No. of Mths
Qtr. Ending
3
Dec-16
*
3
Mar-17
*
3
Jun-17
*
3
Sep-17
*
3
Dec-17
*
3
Mar-18
*
3
Jun-18
*
3
Sep-18
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m25,35024,57223,63022,56622,03722,79821,65625,813 
Other income Rs m146513153297-2326961,3821,399 
Turnover Rs m25,49625,08523,78322,86321,80523,49423,03827,212 
Expenses Rs m17,70020,13317,85618,68218,81019,53018,18721,412 
Gross profit Rs m7,6502,6035,7743,8843,2273,2683,4696,073 
Depreciation Rs m625689777752754735794825 
Interest Rs m617697709698705744790851 
Profit before tax Rs m6,5531,7304,4412,7311,5372,4853,2675,796 
Tax Rs m1,7821071,1085894899689371,656 
Profit after tax Rs m4,7701,6233,3342,1411,0471,5162,3304,140 
Gross profit margin %30.210.624.417.214.614.316.023.5 
Effective tax rate %27.26.224.921.631.839.028.728.6 
Net profit margin %18.86.614.19.54.86.710.816.0 
Diluted EPS Rs 17.6 6.0 12.3 7.9 3.9 5.6 8.6 15.3  
Diluted EPS (TTM) Rs 40.5 40.2 44.1 43.7 30.0 29.6 25.9 33.3  
 Subscriber Feature View View   View          
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: Glenmark Pharma 2QFY19 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   INDOCO REMEDIES  FDC LTD.  ASTRAZENECA PHARMA  MERCK LTD  FRESENIUS KABI ONCO.  

Compare GLENMARK PHARMA With:   INDOCO REMEDIES  FDC LTD.  ASTRAZENECA PHARMA  MERCK LTD  FRESENIUS KABI ONCO.  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.

Views on news

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 20, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - PLETHICO PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS